Share on StockTwits

Investment analysts at WallachBeth Capital began coverage on shares of Celsus Therapeutics PLC (NASDAQ:CLTX) in a note issued to investors on Tuesday, reports. The firm set a “buy” rating and a $17.00 price target on the stock. WallachBeth Capital’s price target suggests a potential upside of 198.25% from the stock’s previous close.

Shares of Celsus Therapeutics PLC (NASDAQ:CLTX) opened at 5.77 on Tuesday. Celsus Therapeutics PLC has a 1-year low of $4.63 and a 1-year high of $11.90. The stock has a 50-day moving average of $5.98 and a 200-day moving average of $6.34. The company’s market cap is $32.1 million.

Celsus Therapeutics PLC is a biopharmaceutical company. The Company is focused on the discovery and development of non-steroidal, synthetic anti-inflammatory drugs.

The Fly On The Wall

Receive News & Ratings for Celsus Therapeutics PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celsus Therapeutics PLC and related companies with Analyst Ratings Network's FREE daily email newsletter.